Brand & Product Security

GS1 US Executive provides insight on how pharma supply can speed up the process of complying with regulations.

In an interview at LogiPharma USA 2023 with Pharma Commerce Editor Nicholas Saraceno, Tracy Nasarenko, Sr. Director of Community Engagement for Pharmaceuticals, GS1 US highlights her “DSCSA—Final Checks to Have Before Deadlines.”

LogiPharma session reminds attendees of what to review, as far as DSCSA compliance is concerned.

Pharma Commerce converges on Nation's Capital for HDA Traceability Seminar.

Questions and considerations for pharmaceutical companies in designing and executing strategies to curb the incidence of fake drugs.

Stakeholders uncover the obstacles surrounding the industry onboarding process.

Attendees meet to discuss operational issues related to traceability implementation.

Session offers information on industry readiness, plus an overview of a phase implementation recommendation.

Event’s first session aims to analyze the legislation’s implementation, as FDA enforcement is delayed until November 2024.

Software allows pharmacies to meet legislation’s upcoming Nov. 27 deadline.

The legislation’s deadline for compliance is knocking on the door. Pharma Commerce offers a synopsis of how the Drug Supply Chain Security Act has progressed over the past decade.

DSCSA compliance was also top of mind at the event.

The series’ marking heads help deliver codes to support both product traceability and anti-counterfeiting efforts.

Latest Q4 2022 results show some progress, but 100% readiness by November looks doubtful.

As a November deadline looms for industry compliance with an interoperable system for product tracing, there is more urgency in the US pharma supply chain.

Industry is still scrambling to handle clerical errors of DSCSA transactions.

Event—taking place in Indianapolis—places supply chain education at the forefront.

The Pulse online service will provide free resources to enable pharmacy to meet drug traceability rules.

With the help of traceability, new feature prioritizes efficiency and safety, from production to patient.

Meanwhile, PDG issues more DSCSA guidance on data interoperability.

Citing FDA’s slow guidance, the American Pharmacists Association is requesting delay in November 2023 DSCSA enforcement.

If there’s anything we learned from the pandemic, it’s the critical need to analyze patient outcome data in real time to stay informed on the safety and efficacy of treatments in the real world

Features an ATP solution to allow for efficiency

The clock is ticking on a massive effort to bring interoperable, electronic tracking of pharma shipments in the US

A recommended checklist for manufacturers as they enlist distributor and 3PL support—and the important questions they should be asking themselves

Pressure is mounting ahead of looming unit-level serialization required by the Drug Supply Chain Security Act—necessitating a wide scope of collaboration on compliance

Outlining the work of the Open Credentialing Initiative in establishing digital proof of identity, licensure status, and authorship using digital wallets and verifiable credentials

From November 2023, the Drug Supply Chain Security Act requires healthcare manufacturers, distributors, providers, and dispensers to exchange the serialized item-level product information that has been collected, standardized, and digitized. Hitting this deadline hinges on intensive collaboration between manufacturers and their supply chain partners that must begin now

More biologic-based therapies translates into more cold chain activity. As yet, new cellular and genetic therapies are a minute part of the overall market.